Industry Briefs October 2022

PatientPoint Expands into Ophthalmology

PatientPoint has acquired Rendia, the leading provider of point-of-care content for eye care providers sold on a subscription basis. With PatientPoint’s expansion into ophthalmology and optometry, the company’s tech-enabled point-of-care network now engages healthcare providers and patients across 20 medical specialties. Rendia has offered its award-winning content platform for more than 20 years and boasts a 90% retention rate. Its engagement software helps 8,000+ eye care providers improve patient outcomes, enhance the patient experience, and generate incremental revenue growth through improving patient acceptance of recommended medical and surgical procedures.

Through the acquisition, PatientPoint gains access to Rendia’s technology platform, provider portal, and content library, which all offer providers the ability to create and easily upload their own custom content. PatientPoint intends to leverage Rendia’s platform and portal to accelerate expansion into other specialties and markets where custom content creation is critically important. As a result, Rendia customers gain access to additional engagement solutions through PatientPoint to help them deliver continual, connected care across the patient’s entire care journey. The company will now be referred to as Rendia, a PatientPoint company.

The Sparkle of Hope Gala Returns November

After a two-year hiatus due to the pandemic, Community Hope’s Sparkle of Hope Gala will be held in-person November 15th at the Legacy Castle in Pompton Plains, NJ. City of Hope, a Jersey-based non-profit, provides support to veterans and their families. The annual Sparkle of Hope Gala is a fundraiser that assists 1,000 veterans and veteran families with housing stability and mental wellness. The gala also supports Community Hope’s residential programs, serving more than 100 individuals daily in recovery from mental illness.

Community Hope will present the Sparkle of Hope Award this year to two well-deserving honorees, Aaron Graff, Senior Vice President and Chief Commercial Officer at Ferring

Pharmaceuticals and Joseph Papa, Chief Executive Officer at Bausch+Lomb. Their corporations have supported Community Hope for over a decade and they make advocating for the organization’s mission a top priority. The Sparkle of Hope event has raised more than $17 million since 1997, when Fred Hassan first founded the event to enhance community-based services to coincide with pharmaceutical advances in mental health treatment. Sparkle of Hope continues to bring together pharmaceutical, biotechnology, and other related industries in support of a common cause. Hassan, presently Chairman of the Caret Group and Director of Warburg Pincus, continues to serve as Founding Chair of the event.

To attend, visit the events section of Community Hope’s website at

Sharecare Expands Life Sciences Product Suite

Sharecare announced nine new digital solutions designed to engage, educate, and support people in managing their health. The 2023 offerings, which are customized to reach people and caregivers impacted by specific conditions, are purpose-built to support and enable patient-to-provider discussions, while simultaneously educating and motivating individuals. Some of these new products include:

Vital Voices: A multimedia approach to storytelling which showcases real, first-person stories from multicultural and underrepresented populations as they navigate a condition. Vital Voices tells authentic stories through the use of video, audio, photo carousels, and written narratives; and also includes facts, figures, tips, and information tailored to the specific condition and target audience demographics.

The Rare Disease Roadmap: According to the National Institutes of Health, one in 10 people in the U.S. have one of 7,000 known rare diseases. This digital education center aims to help people who suspect they may have or are newly diagnosed with a rare disease to navigate the complexity of the patient journey from diagnosis to treatment.

Patient Connect: This content hub invites patients and caregivers managing a specific chronic disease to share their stories, tips, and words of encouragement for others managing a similar diagnosis.

Inside Out: An immersive tool featuring 3D-animated graphics from the award-winning Sharecare Reality Lab, users visually explore the progression of a disease and the science of their treatment.

Care Collective: In an effort to address the confusion and complexity of building one’s care team, this interactive resource empowers people and their caregivers to understand the role of various clinical specialists and how to optimize these patient-provider partnerships for better outcomes.

“By driving engagement, awareness, and transparency through these new innovative solutions, we look forward to educating, motivating, and inspiring people and caregivers to seek care and treatment that improves their quality of life,” stated Laura Klein, General Manager and Executive Vice President of Life Sciences at Sharecare. “The campaigns and initiatives that these new solutions enable support patients and our partners in manifesting Sharecare’s vision that we are truly all together better.”

Syneos Health and Datavant Expand Partnership

Syneos Health and Datavant are expanding upon their long-standing strategic partnership to further leverage the full suite of capabilities in Datavant Switchboard and Datavant’s large data ecosystem to accelerate the clinical development and commercialization of new therapies for patients. The use of Datavant Switchboard will allow Syneos Health to develop advanced analytics and AI-driven technologies to execute more efficient clinical trials, creating an improved experience for patients, sites, and biopharmaceutical customers. Additionally, the relationship empowers HEOR, Medical Affairs, Market Access, and Commercialization analytics and insights to drive better analysis for Syneos Health’s biopharmaceutical customers’ products.

“Our continuous collaboration with Datavant will deliver to our customers an established clinical trial tokenization capability and the ability for our teams to leverage this approach to develop new, innovative solutions for conducting clinical research and driving product commercialization that is powered by data-driven insights,” Bob Zambon, Vice President, Solution Design, Syneos Health, said in a statement. “We’re excited by the opportunity to further utilize the growing suite of capabilities in Datavant Switchboard to support our clients and sites in accelerating and diversifying their clinical trials.”

Lasso and CMI Media Group Partner with IBM Watson

With IBM Watson’s Advertising Accelerator, Lasso and CMI could predict and serve ad units in real time.

Lasso and CMI Media Group are among the first to leverage IBM Watson’s dynamic creative capabilities for healthcare marketing. The companies partnered with IBM Watson’s Advertising Accelerator to bring hyper-personalized media campaigns to clinical audiences, increasing drug awareness, engagement, and prescription-writing behavior. IBM Watson’s Advertising Accelerator uses AI to predict and serve ad units in real time with the creative

elements that are most likely to drive action among each audience while Lasso’s end-to-end healthcare marketing and analytics capabilities deliver intelligent optimizations and real-world measurement across programmatic channels.

When CMI Media Group ran a campaign from Q4 2021 to Q2 2022 using IBM Watson’s Advertising Accelerator and Lasso’s capabilities, the brand chose various targeting parameters such as first-party and third-party healthcare provider (HCP) audiences including physicians, nurse practitioners (NPs), and physician assistants (PAs) treating and diagnosing the conditions of interest. Lasso also reidentified the audiences after they were exposed to media, enabling them to deterministically attribute real-world prescribing behaviors to each of CMI Media Group’s advertising tactics.

Overall, the combination of audience penetration, creative media, and real-time optimizations drove a 151% increase in conversion rate to the brand’s site and a 40% increase in CTR compared to previous campaigns. Lasso’s reporting revealed a significantly positive impact of media exposure on prescription writing activity and new HCP and patient conversion to the brand.

“This first-in-pharma partnership brought our client industry-leading excellence in targeting, data, personalization, and measurement, allowing us to drive deeper and more meaningful engagements with our HCP audiences,” said Cliff Covey, SVP, Digital Activation, CMI Media Group. “We are committed to innovation that improves patients’ lives, and look forward to continuing on this path given the incredible success of the pilot.”


You May Also Like

Industry Briefs September 2021

Pfizer Is the First to Get Full COVID-19 Vaccine Approval The FDA made the ...

The Immense Benefit of Copay Cards

In the wake of the recent class action lawsuits charging that copay cards constitute ...